Join PhD student Daniel De Los Reyes Helices from the Molecular Neurobiology Group at Kids Research as he explores an innovative approach to treating Rett syndrome.
This seminar highlights how clinically available supplements (safe, affordable, and free from major regulatory hurdles) could offer faster therapeutic options compared to traditional drug development.
Why attend?
Mr. Daniel De Los Reyes Helices is a PhD student within the Molecular Neurobiology Group at Kids Research, Children’s Hospital at Westmead & Children’s Medical Research Institute. Daniel’s PhD project focuses on identifying therapeutic options for neurodevelopmental rare diseases, currently centered on Rett Syndrome (RTT).
This study investigates clinically available supplements as a faster and more accessible therapeutic strategy for Rett Syndrome. Unlike new drugs or AAV therapies, supplements have established safety records, fewer regulatory barriers, and no patent costs, enabling affordable and immediate clinical translation. Using MECP2-mutant iPSC-derived neurons, their lab applied transcriptomic and proteomic screening to identify compounds that restore key disrupted pathways, establishing a framework for rapidly deployable and combinatorial RTT interventions.
This Kids Research seminar was coordinated by Dr Yuyan Chen, Children’s Cancer Research Unit, Dr Frances Evesson, Kids Neuroscience Centre, and Kids Research Communications team.